Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

APREA THERAPEUTICS, INC.

(APRE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société APREA THERAPEUTICS, INC.
01/13APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Di..
AQ
01/06Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on T..
AQ
2021Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant..
AQ
2021Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azaci..
AQ
2021APREA THERAPEUTICS : Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Ma..
PU
2021APREA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid M..
AQ
2021Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on ..
PU
2021APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
2021Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on ..
GL
2021Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd..
GL
2021Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd..
GL
2021APREA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021APREA THERAPEUTICS : Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advan..
AQ
2021APREA THERAPEUTICS : to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Soli..
AQ
2021APREA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
2021APREA THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Provides Update on ..
PU
2021APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Other Events, Fi..
AQ
2021Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on..
GL
2021Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program
GL
2021APREA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2021APREA THERAPEUTICS : Announces a Partial Clinical Hold on Myeloid Malignancy Programs
AQ
2021APREA THERAPEUTICS : Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azaci..
AQ
2021APREA THERAPEUTICS : Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine ..
AQ
2021APREA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2021Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit
GL
2021Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Con..
GL
2021APREA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
2021APREA THERAPEUTICS : Reports First Quarter 2021 Financial Results and Provides Update on B..
AQ
2021Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021
GL
2021Aprea Therapeutics Receives FDA Orphan Drug Designation for Eprenetapopt for the Treatm..
GL
2021APREA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
2021Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Prov..
GL
2021APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Di..
AQ
2021Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on T..
GL
2020APREA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020APREA THERAPEUTICS : Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetap..
AQ
2020Aprea Therapeutics Receives FDA Fast Track Designation for Eprenetapopt in the Treatmen..
GL
2020APREA THERAPEUTICS : to Participate in the 32nd Annual Piper Sandler Healthcare Conference
AQ
2020Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conferenc..
GL
2020APREA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
2020APREA THERAPEUTICS : Reports Third Quarter 2020 Financial Results and Provides Update on B..
AQ
2020Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on ..
GL
2020APREA THERAPEUTICS : to Highlight Changing Treatment Paradigm in MDS as well as Developmen..
AQ
2020Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Developme..
GL
2020APREA THERAPEUTICS : Launches Disease Awareness Website for Healthcare Professionals, p53r..
AQ
2020Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53..
GL
2020APREA THERAPEUTICS : Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Ge..
AQ
2020Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-G..
GL
2020APREA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Regulation FD Disclo..
AQ
2020APREA THERAPEUTICS : Appoints Michael A. Kelly to Board of Directors
AQ
2020Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors
GL
2020APREA THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing R..
AQ
2020APREA THERAPEUTICS : Promotes Gregory S. Wessels to Chief Commercial Officer and Announces..
AQ
2020Aprea Therapeutics Promotes Gregory S. Wessels to Chief Commercial Officer and Announce..
GL
2020Aprea Therapeutics to Present at Upcoming Investor Conferences
GL
2020APREA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
2020Aprea Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on..
GL
2020Aprea Therapeutics Announces Expansion of Clinical Trial Evaluating Eprenetapopt for th..
GL
2020APREA THERAPEUTICS, INC. : Change in Directors or Principal Officers, Submission of Matter..
AQ
2020Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Boar..
GL
2020Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (..
GL
2020Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant M..
GL
2020Aprea Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference
GL
2020APREA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
2020Aprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on ..
GL
2020Aprea Therapeutics Launches New Corporate Website - www.aprea.com
GL
2020APREA THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
2020APREA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
2020Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Prov..
GL
2020Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial
GL
2020Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combina..
GL
2020APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Di..
AQ
2020Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on T..
GL
Upcoming event on APREA THERAPEUTICS, INC.